Novo Nordisk’s Weight Loss Blockbuster Faces Setback From US Compounding Surge, Forecast Trimmed

Louis Velazquez

All NewsMay 7, 2025

Novo Nordisk slashed its 2025 sales forecast citing lower-than-expected penetration of its branded GLP-1 weight loss and diabetes treatments.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent